CL Quantitative Stock Analysis

Validea's guru fundamental report indicates that Colgate-Palmolive (CL) receives a 68% rating based on their Patient Investor model, which is inspired by Warren Buffett's investment strategy focused on predictable profitability, low debt, and reasonable valuation. While CL passes criteria related to earnings predictability, debt service, free cash flow, use of retained earnings, share repurchase, and initial/expected rate of return, it fails tests for return on equity and return on total capital.

Analysis

Validea's fundamental report on Colgate-Palmolive Co. (CL), utilizing the Patient Investor model inspired by Warren Buffett, assigns the company a rating of 68%. This score is below the typical 80% threshold indicating strategy interest and well below the 90% mark for strong interest. The analysis reveals a mixed performance against the model's criteria: CL passes on key aspects such as earnings predictability, debt service, free cash flow generation, use of retained earnings, share repurchase programs, and both initial and expected rates of return. These passes align with the strategy's preference for firms with long-term, predictable profitability and low debt. However, CL notably fails the tests for Return on Equity (ROE) and Return on Total Capital (ROTC), suggesting potential concerns regarding its efficiency in generating profits from shareholder equity and total capital employed. The overall sentiment for CL is mildly positive, but the quantitative screening presents specific areas of weakness that temper a wholly bullish interpretation based on this particular investment strategy.

Key Decisions for Investors

• Investors following Buffett-style principles should note CL's moderate score and specific failures in ROE and ROTC, suggesting a cautious approach despite strengths in earnings predictability and debt management.
• Further due diligence is warranted to understand the drivers behind the weak return on capital metrics before committing capital, as these are significant factors for long-term value investors.
• While CL exhibits several positive fundamental traits such as consistent earnings and shareholder-friendly capital returns via buybacks, the current Validea assessment indicates it may not fully meet the stringent criteria of the Patient Investor model, warranting a deeper look or consideration of these weaknesses in position sizing.